Last reviewed · How we verify

NCT03816761

Research Study to Look at Fast-acting Insulin Aspart With the Insulin Pump System 'iLet™' in Adults With Type 1 Diabetes

Completed Phase 2 Results posted Last updated 11 June 2020
What this trial tests

Phase 2 trial testing Fast-acting insulin aspart in Diabetes Mellitus, Type 1 in 24 participants. Completed in 10 June 2019.

Timeline
25 February 2019
Primary endpoint
31 May 2019
10 June 2019

Quick facts

Lead sponsorNovo Nordisk A/S
PhasePhase 2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingdouble
Primary purposetreatment
Enrollment24
Start date25 February 2019
Primary completion31 May 2019
Estimated completion10 June 2019
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Novo Nordisk A/S — full company profile →

Who can join

Adults 18 to 75, any sex, with Diabetes Mellitus, Type 1. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Time in Low Interstitial Glucose (Defined as Below 54 mg/dL [3 mmol/L]) From Initiation of Treatment (Day 1) to End of Treatment (Day 7) (Percentage) Primary · Day 1 to day 7

Interstitial glucose: glucose measured in interstitial fluid. Time in low interstitial glucose (defined as below 54 mg/dL \[3 mmol/L\]) from initiation of treatment (day 1) to end of treatment (day 7). Time spent in low interstitial glucose is calculated as the percentage of available interstitial glucose values below the threshold.

GroupValue95% CI
t50 Faster Aspart Cohort 10.98± 0.72
t65 Faster Aspart Cohort 10.89± 1.16
t40 Faster Aspart Cohort 20.69± 0.50
t65 Faster Aspart Cohort 20.50± 0.79
t30 Faster Aspart Cohort 30.61± 0.56
t65 Faster Aspart Cohort 30.37± 0.41
Time in Low Interstitial Glucose (Defined as Below 54 mg/dL [3 mmol/L]) From Initiation of Treatment (Day 1) to End of Treatment (Day 7) (Percentage) - Median Primary · Day 1 to day 7

Interstitial glucose: glucose measured in interstitial fluid. Time in low interstitial glucose (defined as below 54 mg/dL \[3 mmol/L\]) from initiation of treatment (day 1) to end of treatment (day 7). Time spent in low interstitial glucose is calculated as the percentage of available interstitial glucose values below the threshold.

GroupValue95% CI
t50 Faster Aspart Cohort 10.930.2 – 2.2
t65 Faster Aspart Cohort 10.420.1 – 3.6
t40 Faster Aspart Cohort 20.750.0 – 1.4
t65 Faster Aspart Cohort 20.200.0 – 2.3
t30 Faster Aspart Cohort 30.580.0 – 1.4
t65 Faster Aspart Cohort 30.290.1 – 1.3
Number of Treatment Emergent Severe Hypoglycaemic Episodes Secondary · Day 1 to day 7

Number of treatment emergent severe hypoglycaemic episodes from initiation of treatment (day 1) to end of treatment (day 7). Treatment emergent is defined as an episode that has onset in the period from initiation of treatment to end of treatment. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon or take other corrective actions. Plasma glucose (PG) concentrations may not be available during an event, but neurological recovery following the return of PG to normal is considered sufficient evidence that the event was induced by

GroupValue95% CI
t50 Faster Aspart Cohort 20
t65 Faster Aspart Cohort 10
t40 Faster Aspart Cohort 20
t65 Faster Aspart Cohort 20
t30 Faster Aspart Cohort 30
t65 Faster Aspart Cohort 30
Number of Self-manageable (Able to Self-treat) Treatment Emergent Hypoglycaemic Episodes That Require Oral Carbohydrate Intervention Per Day Secondary · Day 1 to day 7

Mean number of self-manageable (able to self-treat) treatment emergent hypoglycaemic episodes that require oral carbohydrate intervention per day. Self-manageable (able to self-treat) hypoglycaemic episodes that require oral carbohydrate intervention per day is calculated as the sum of all hypoglycaemic episodes where the subject is able to self-treat and that require oral carbohydrate intervention divided by the actual duration of the treatment period in days. Treatment emergent is defined as an episode that has onset in the period from initiation of treatment to end of treatment.

GroupValue95% CI
t50 Faster Aspart Cohort 21.01± 0.44
t65 Faster Aspart Cohort 10.87± 0.49
t40 Faster Aspart Cohort 11.06± 0.57
t65 Faster Aspart Cohort 20.68± 0.43
t30 Faster Aspart Cohort 30.86± 0.55
t65 Faster Aspart Cohort 30.51± 0.36
Number of Treatment Emergent Overall Hypoglycaemic Episodes Classified According to the American Diabetes Association (ADA) Definition Secondary · Day 1 to day 7

ADA classification of hypoglycaemia: 1. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon or take other corrective actions. 2. Asymptomatic hypoglycaemia: An episode not accompanied by typical symptoms of hypoglycaemia, but with a measured PG concentration ≤3.9 mmol/L (70 mg/dL). 3. Documented symptomatic hypoglycaemia: An episode during which typical symptoms of hypoglycaemia are accompanied by a measured PG concentration ≤ 3.9 mmol/L (70 mg/dL). 4. Pseudo-hypoglycaemia: An episode during which the person with diabetes repor

Severe hypoglycaemia
GroupValue95% CI
t65 Faster Aspart Cohort 10
t50 Faster Aspart Cohort 10
t65 Faster Aspart Cohort 20
t40 Faster Aspart Cohort 20
t65 Faster Aspart Cohort 30
t30 Faster Aspart Cohort 30
Documented symptomatic hypoglycaemia
GroupValue95% CI
t65 Faster Aspart Cohort 136
t50 Faster Aspart Cohort 138
t65 Faster Aspart Cohort 224
t40 Faster Aspart Cohort 242
t65 Faster Aspart Cohort 317
t30 Faster Aspart Cohort 325
Asymptomatic hypoglycaemia
GroupValue95% CI
t65 Faster Aspart Cohort 19
t50 Faster Aspart Cohort 115
t65 Faster Aspart Cohort 28
t40 Faster Aspart Cohort 26
t65 Faster Aspart Cohort 34
t30 Faster Aspart Cohort 39
Probable symptomatic hypoglycaemia
GroupValue95% CI
t65 Faster Aspart Cohort 14
t50 Faster Aspart Cohort 12
t65 Faster Aspart Cohort 23
t40 Faster Aspart Cohort 23
t65 Faster Aspart Cohort 31
t30 Faster Aspart Cohort 35
Pseudo-hypoglycaemia
GroupValue95% CI
t65 Faster Aspart Cohort 13
t50 Faster Aspart Cohort 18
t65 Faster Aspart Cohort 23
t40 Faster Aspart Cohort 26
t65 Faster Aspart Cohort 33
t30 Faster Aspart Cohort 36
Number of Treatment Emergent Overall Hypoglycaemic Episodes Classified According to the Novo Nordisk Classification Secondary · Day 1 to day 7

Overall hypoglycaemia count according to Novo Nordisk classification. Novo Nordisk classification of hypoglycaemia: 1. Severe hypoglycaemia according to the ADA classification. 2. Symptomatic BG confirmed hypoglycaemia: An episode that is BG confirmed by PG value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. 3. Asymptomatic BG confirmed hypoglycaemia: An episode that is BG confirmed by PG value \<3.1 mmol/L (56 mg/dL) without symptoms consistent with hypoglycaemia. 4. BG confirmed hypoglycaemia: The union of 2. and 3. 5. Severe or BG confirmed symptomatic hypoglycaemia:

Severe hypoglycaemia
GroupValue95% CI
t65 Faster Aspart Cohort 10
t50 Faster Aspart Cohort 10
t65 Faster Aspart Cohort 20
t40 Faster Aspart Cohort 20
t65 Faster Aspart Cohort 30
t30 Faster Aspart Cohort 30
Symptomatic BG confirmed hypoglycaemia
GroupValue95% CI
t65 Faster Aspart Cohort 113
t50 Faster Aspart Cohort 112
t65 Faster Aspart Cohort 24
t40 Faster Aspart Cohort 213
t65 Faster Aspart Cohort 36
t30 Faster Aspart Cohort 310
Asymptomatic BG confirmed hypoglycaemia
GroupValue95% CI
t65 Faster Aspart Cohort 13
t50 Faster Aspart Cohort 13
t65 Faster Aspart Cohort 23
t40 Faster Aspart Cohort 21
t65 Faster Aspart Cohort 31
t30 Faster Aspart Cohort 32
BG confirmed hypoglycaemia
GroupValue95% CI
t65 Faster Aspart Cohort 116
t50 Faster Aspart Cohort 115
t65 Faster Aspart Cohort 27
t40 Faster Aspart Cohort 214
t65 Faster Aspart Cohort 37
t30 Faster Aspart Cohort 312
Severe or BG confirmed symptomatic hypoglycaemia
GroupValue95% CI
t65 Faster Aspart Cohort 113
t50 Faster Aspart Cohort 112
t65 Faster Aspart Cohort 24
t40 Faster Aspart Cohort 213
t65 Faster Aspart Cohort 36
t30 Faster Aspart Cohort 310
Severe or BG confirmed hypoglycaemia
GroupValue95% CI
t65 Faster Aspart Cohort 116
t50 Faster Aspart Cohort 115
t65 Faster Aspart Cohort 27
t40 Faster Aspart Cohort 214
t65 Faster Aspart Cohort 37
t30 Faster Aspart Cohort 312
Number of Treatment Emergent Daytime Hypoglycaemic Episodes Classified According to the American Diabetes Association (ADA) Definition Secondary · Day 1 to day 7 (in both the treatment periods)

ADA classification of hypoglycaemia: 1. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon or take other corrective actions. 2. Asymptomatic hypoglycaemia: An episode not accompanied by typical symptoms of hypoglycaemia, but with a measured PG concentration ≤3.9 mmol/L (70 mg/dL). 3. Documented symptomatic hypoglycaemia: An episode during which typical symptoms of hypoglycaemia are accompanied by a measured PG concentration ≤ 3.9 mmol/L (70 mg/dL). 4. Pseudo-hypoglycaemia: An episode during which the person with diabetes repor

Severe hypoglycaemia
GroupValue95% CI
t65 Faster Aspart Cohort 10
t50 Faster Aspart Cohort 10
t65 Faster Aspart Cohort 20
t40 Faster Aspart Cohort 20
t65 Faster Aspart Cohort 30
t30 Faster Aspart Cohort 30
Documented symptomatic hypoglycaemia
GroupValue95% CI
t65 Faster Aspart Cohort 130
t50 Faster Aspart Cohort 131
t65 Faster Aspart Cohort 221
t40 Faster Aspart Cohort 235
t65 Faster Aspart Cohort 314
t30 Faster Aspart Cohort 322
Asymptomatic hypoglycaemia
GroupValue95% CI
t65 Faster Aspart Cohort 15
t50 Faster Aspart Cohort 111
t65 Faster Aspart Cohort 25
t40 Faster Aspart Cohort 24
t65 Faster Aspart Cohort 34
t30 Faster Aspart Cohort 37
Probable symptomatic hypoglycaemia
GroupValue95% CI
t65 Faster Aspart Cohort 13
t50 Faster Aspart Cohort 12
t65 Faster Aspart Cohort 23
t40 Faster Aspart Cohort 22
t65 Faster Aspart Cohort 30
t30 Faster Aspart Cohort 34
Pseudo-hypoglycaemia
GroupValue95% CI
t65 Faster Aspart Cohort 12
t50 Faster Aspart Cohort 15
t65 Faster Aspart Cohort 23
t40 Faster Aspart Cohort 26
t65 Faster Aspart Cohort 32
t30 Faster Aspart Cohort 36
Number of Treatment Emergent Daytime Hypoglycaemic Episodes Classified According to the Novo Nordisk Classification Secondary · Day 1 to day 7

Number of daytime hypoglycaemic episodes according to Novo Nordisk classification. Novo Nordisk classification of hypoglycaemia: 1. Severe hypoglycaemia according to the ADA classification. 2. Symptomatic BG confirmed hypoglycaemia: An episode that is BG confirmed by PG value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. 3. Asymptomatic BG confirmed hypoglycaemia: An episode that is BG confirmed by PG value \<3.1 mmol/L (56 mg/dL) without symptoms consistent with hypoglycaemia. 4. BG confirmed hypoglycaemia: The union of 2. and 3. 5. Severe or BG confirmed symptomatic h

Severe hypoglycaemia
GroupValue95% CI
t65 Faster Aspart Cohort 10
t50 Faster Aspart Cohort 10
t65 Faster Aspart Cohort 20
t40 Faster Aspart Cohort 20
t65 Faster Aspart Cohort 30
t30 Faster Aspart Cohort 30
Symptomatic BG confirmed hypoglycaemia
GroupValue95% CI
t65 Faster Aspart Cohort 112
t50 Faster Aspart Cohort 19
t65 Faster Aspart Cohort 23
t40 Faster Aspart Cohort 29
t65 Faster Aspart Cohort 33
t30 Faster Aspart Cohort 39
Asymptomatic BG confirmed hypoglycaemia
GroupValue95% CI
t65 Faster Aspart Cohort 12
t50 Faster Aspart Cohort 11
t65 Faster Aspart Cohort 22
t40 Faster Aspart Cohort 20
t65 Faster Aspart Cohort 31
t30 Faster Aspart Cohort 32
BG confirmed hypoglycaemia
GroupValue95% CI
t65 Faster Aspart Cohort 114
t50 Faster Aspart Cohort 110
t65 Faster Aspart Cohort 25
t40 Faster Aspart Cohort 29
t65 Faster Aspart Cohort 34
t30 Faster Aspart Cohort 311
Severe or BG confirmed symptomatic hypoglycaemia
GroupValue95% CI
t65 Faster Aspart Cohort 112
t50 Faster Aspart Cohort 19
t65 Faster Aspart Cohort 23
t40 Faster Aspart Cohort 29
t65 Faster Aspart Cohort 33
t30 Faster Aspart Cohort 39
Severe or BG confirmed hypoglycaemia
GroupValue95% CI
t65 Faster Aspart Cohort 114
t50 Faster Aspart Cohort 110
t65 Faster Aspart Cohort 25
t40 Faster Aspart Cohort 29
t65 Faster Aspart Cohort 34
t30 Faster Aspart Cohort 311
Number of Treatment Emergent Nocturnal Hypoglycaemic Episodes Classified According to the American Diabetes Association (ADA) Definition Secondary · Day 1 to day 7

ADA classification of hypoglycaemia: 1. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon or take other corrective actions. 2. Asymptomatic hypoglycaemia: An episode not accompanied by typical symptoms of hypoglycaemia, but with a measured PG concentration ≤3.9 mmol/L (70 mg/dL). 3. Documented symptomatic hypoglycaemia: An episode during which typical symptoms of hypoglycaemia are accompanied by a measured PG concentration ≤ 3.9 mmol/L (70 mg/dL). 4. Pseudo-hypoglycaemia: An episode during which the person with diabetes repor

Severe hypoglycaemia
GroupValue95% CI
t65 Faster Aspart Cohort 10
t50 Faster Aspart Cohort 10
t65 Faster Aspart Cohort 20
t40 Faster Aspart Cohort 20
t65 Faster Aspart Cohort 30
t30 Faster Aspart Cohort 30
Documented symptomatic hypoglycaemia
GroupValue95% CI
t65 Faster Aspart Cohort 16
t50 Faster Aspart Cohort 17
t65 Faster Aspart Cohort 23
t40 Faster Aspart Cohort 27
t65 Faster Aspart Cohort 33
t30 Faster Aspart Cohort 33
Asymptomatic hypoglycaemia
GroupValue95% CI
t65 Faster Aspart Cohort 14
t50 Faster Aspart Cohort 14
t65 Faster Aspart Cohort 23
t40 Faster Aspart Cohort 22
t65 Faster Aspart Cohort 30
t30 Faster Aspart Cohort 32
Probable symptomatic hypoglycaemia
GroupValue95% CI
t65 Faster Aspart Cohort 11
t50 Faster Aspart Cohort 10
t65 Faster Aspart Cohort 20
t40 Faster Aspart Cohort 21
t65 Faster Aspart Cohort 31
t30 Faster Aspart Cohort 31
Pseudo-hypoglycaemia
GroupValue95% CI
t65 Faster Aspart Cohort 11
t50 Faster Aspart Cohort 13
t65 Faster Aspart Cohort 20
t40 Faster Aspart Cohort 20
t65 Faster Aspart Cohort 31
t30 Faster Aspart Cohort 30
Number of Treatment Emergent Nocturnal Hypoglycaemic Episodes Classified According to the Novo Nordisk Classification Secondary · Day 1 to day 7 (in both the treatment periods)

Number of nocturnal (from time 00:01-05:59 both inclusive) hypoglycaemic episodes according to Novo Nordisk classification. Novo Nordisk classification of hypoglycaemia: 1. Severe hypoglycaemia according to the ADA classification. 2. Symptomatic BG confirmed hypoglycaemia: An episode that is BG confirmed by PG value \<3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia. 3. Asymptomatic BG confirmed hypoglycaemia: An episode that is BG confirmed by PG value \<3.1 mmol/L (56 mg/dL) without symptoms consistent with hypoglycaemia. 4. BG confirmed hypoglycaemia: The union of 2. and 3

Severe hypoglycaemia
GroupValue95% CI
t65 Faster Aspart Cohort 10
t50 Faster Aspart Cohort 10
t65 Faster Aspart Cohort 20
t40 Faster Aspart Cohort 20
t65 Faster Aspart Cohort 30
t30 Faster Aspart Cohort 30
Symptomatic BG confirmed hypoglycaemia
GroupValue95% CI
t65 Faster Aspart Cohort 11
t50 Faster Aspart Cohort 13
t65 Faster Aspart Cohort 21
t40 Faster Aspart Cohort 24
t65 Faster Aspart Cohort 33
t30 Faster Aspart Cohort 31
Asymptomatic BG confirmed hypoglycaemia
GroupValue95% CI
t65 Faster Aspart Cohort 11
t50 Faster Aspart Cohort 12
t65 Faster Aspart Cohort 21
t40 Faster Aspart Cohort 21
t65 Faster Aspart Cohort 30
t30 Faster Aspart Cohort 30
BG confirmed hypoglycaemia
GroupValue95% CI
t65 Faster Aspart Cohort 12
t50 Faster Aspart Cohort 15
t65 Faster Aspart Cohort 22
t40 Faster Aspart Cohort 25
t65 Faster Aspart Cohort 33
t30 Faster Aspart Cohort 31
Severe or BG confirmed symptomatic hypoglycaemia
GroupValue95% CI
t65 Faster Aspart Cohort 11
t50 Faster Aspart Cohort 13
t65 Faster Aspart Cohort 21
t40 Faster Aspart Cohort 24
t65 Faster Aspart Cohort 33
t30 Faster Aspart Cohort 31
Severe or BG confirmed hypoglycaemia
GroupValue95% CI
t65 Faster Aspart Cohort 12
t50 Faster Aspart Cohort 15
t65 Faster Aspart Cohort 22
t40 Faster Aspart Cohort 25
t65 Faster Aspart Cohort 33
t30 Faster Aspart Cohort 31
Time in Interstitial Glucose Range Was Defined as 70-180 mg/dL (3.9-10 mmol/L) From Initiation of Treatment (Day 1) to End of Treatment (Day 7) (Percentages) Secondary · Day 1 to day 7

Time in interstitial glucose range defined as 70-180 mg/dL (3.9-10 mmol/L) from initiation of treatment (day 1) to end of treatment (day 7). Time spent in interstitial glucose range is calculated as the percentage of available interstitial glucose values above or equal to the low threshold and below or equal to the high threshold.

GroupValue95% CI
t50 Faster Aspart Cohort 170.87± 9.35
t65 Faster Aspart Cohort 166.79± 10.39
t40 Faster Aspart Cohort 273.93± 6.14
t65 Faster Aspart Cohort 270.44± 8.49
t30 Faster Aspart Cohort 378.32± 6.96
t65 Faster Aspart Cohort 373.82± 11.79
Mean Interstitial-glucose Level Secondary · Day 1 to day 7

Mean interstitial glucose level is calculated as the average of the available interstitial glucose values.

GroupValue95% CI
t50 Faster Aspart Cohort 1150.3± 7.8
t65 Faster Aspart Cohort 1157.7± 11.0
t40 Faster Aspart Cohort 2150.1± 8.5
t65 Faster Aspart Cohort 2157.6± 11.5
t30 Faster Aspart Cohort 3144.1± 7.1
t65 Faster Aspart Cohort 3152.5± 11.4

Adverse events — posted to ClinicalTrials.gov

Time frame: From the first trial-related activity (screening, day -14) after obtaining informed consent and until the follow up visit (treatment days 7 in both periiods+7 days follow-up). Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

t50 Faster Aspart Cohort 1
Serious: 0/8 (0%)
Deaths: 0/8
t65 Faster Aspart Cohort 1
Serious: 0/8 (0%)
Deaths: 0/8
t40 Faster Aspart Cohort 2
Serious: 0/8 (0%)
Deaths: 0/8
t65 Faster Aspart Cohort 2
Serious: 0/8 (0%)
Deaths: 0/8
t30 Faster Aspart Cohort 3
Serious: 0/8 (0%)
Deaths: 0/8
t65 Faster Aspart Cohort 3
Serious: 0/7 (0%)
Deaths: 0/7
Other adverse events (5 terms — click to expand)

ReactionSystemt50 Faster Aspart Cohort 1t65 Faster Aspart Cohort 1t40 Faster Aspart Cohort 2t65 Faster Aspart Cohort 2t30 Faster Aspart Cohort 3t65 Faster Aspart Cohort 3
HyperglycaemiaMetabolism and nutrition disorders——————
Infusion site reactionGeneral disorders——————
PyrexiaGeneral disorders——————
Viral upper respiratory tract infectionInfections and infestations——————
VomitingGastrointestinal disorders——————

Data from ClinicalTrials.gov NCT03816761 adverse events section.

Sponsor's own description

The iLet™ is a new insulin pump that is programmed to work with a Continuous Glucose Monitoring (CGM) device. This is to give participants insulin automatically. The CGM device is already available for sale. The iLet™ is not yet approved for use. Fast-acting insulin aspart is a type of insulin that doctors can already prescribe for use with insulin pens, but not for use in an insulin pump. This study is to test how safe fast acting insulin aspart is when used with different insulin delivery settings in the iLet™ in people with type 1 diabetes. Participants will get fast-acting insulin aspart as participants' insulin and use the iLet™ as participants' insulin pump with a CGM device. Participants' iLet™ will be set to 2 different insulin delivery settings for 7 days on each setting. The setting participants get first is decided by chance. The study will last for about 5 to 9 weeks. Participants will have 4 visits and 1 phone contact with the study or staff.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Recent Advances in Insulin Therapy.
    Wilson LM, Castle JR. · · 2020 · cited 35× · PMID 32310681 · DOI 10.1089/dia.2020.0065
  2. A Comprehensive Review of the Evolution of Insulin Development and Its Delivery Method.
    Sugumar V, Ang KP, Alshanon AF, Sethi G, et al · · 2022 · cited 14× · PMID 35890301 · DOI 10.3390/pharmaceutics14071406
  3. Improvements in Glycemic Control Achieved by Altering the t<sub>max</sub> Setting in the iLet<sup>®</sup> Bionic Pancreas When Using Fast-Acting Insulin Aspart: A Randomized Trial.
    Russell SJ, Balliro C, Ekelund M, El-Khatib F, et al · · 2021 · cited 11× · PMID 34146238 · DOI 10.1007/s13300-021-01087-x
  4. 56<sup>th</sup> EASD Annual Meeting of the European Association for the Study of Diabetes : 21-25 September 2020.
    · 2020 · cited 9× · PMID 32840677 · DOI 10.1007/s00125-020-05221-5

Verify or expand the search:

Other trials of Fast-acting insulin aspart

Trials testing the same drug.

Other recruiting trials for Diabetes Mellitus, Type 1

Currently open trials in the same condition.

Other Novo Nordisk A/S trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03816761.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing